Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
(
2 selected
)
Type
Guidance (412)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Apply filters
Showing 101 to 150 of 423
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Digital front door for people accessing NHS Talking Therapies
Health technology evaluation
23 June 2025
Digital technologies to support self-management of COPD: early value assessment
Health technology evaluation
19 December 2024
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Health technology evaluation
3 April 2025
Direct skeletal fixation of limb prostheses using intraosseous transcutaneous implants
Interventional procedures guidance
12 December 2024
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Technology appraisal guidance
26 March 2025
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415
Technology appraisal guidance
TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Technology appraisal guidance
TBC
Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment
Health technology evaluation
12 May 2025
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
Technology appraisal guidance
TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235
Technology appraisal guidance
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
NICE guideline
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Technology appraisal guidance
TBC
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073
Technology appraisal guidance
23 July 2025
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]
Technology appraisal guidance
TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Technology appraisal guidance
TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317
Technology appraisal guidance
21 May 2025
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]
Technology appraisal guidance
26 March 2025
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Technology appraisal guidance
TBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)
NICE guideline
31 March 2025
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
Technology appraisal guidance
TBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]
Technology appraisal guidance
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Technology appraisal guidance
25 June 2025
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]
Technology appraisal guidance
TBC
Elafibranor for treating primary biliary cholangitis [ID6331]
Technology appraisal guidance
13 November 2024
Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults
Interventional procedures guidance
29 January 2025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]
Technology appraisal guidance
11 December 2024
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
Technology appraisal guidance
TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Technology appraisal guidance
23 July 2025
Endometriosis: diagnosis and management - diagnosing endometriosis
NICE guideline
11 November 2024
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction
Interventional procedures guidance
14 November 2024
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
Interventional procedures guidance
TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Technology appraisal guidance
15 June 2022
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]
Technology appraisal guidance
4 June 2025
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]
Technology appraisal guidance
TBC
Epilepsies in children, young people and adults (extraordinary review)
NICE guideline
TBC
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]
Technology appraisal guidance
27 November 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
Technology appraisal guidance
TBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]
Technology appraisal guidance
TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Technology appraisal guidance
26 February 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Technology appraisal guidance
TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920
Technology appraisal guidance
TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
Technology appraisal guidance
TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
Diagnostics guidance
TBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)
NICE guideline
26 March 2025
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Technology appraisal guidance
20 November 2024
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
Technology appraisal guidance
TBC
Fertility problems: assessment and treatment
NICE guideline
6 August 2025
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]
Technology appraisal guidance
21 May 2025
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Technology appraisal guidance
TBC
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Technology appraisal guidance
TBC
Previous page
1
2
Current page
3
4
5
…
9
Page
3
of
9
Next page
Results per page
10
25
50
All
Back to top